The short version of peptide hormone fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-10. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
== Description line == The description line (defline) or header/identifier line, which begins with ">", gives a name and/or a unique identifier for the sequence, and may also contain additional information. In a deprecated practice, the header line sometimes contained more than one header, separated by a ^A (Control-A) character. In the original Pearson FASTA format, one or more comments, distinguished by a semi-colon at the beginning of the line, may occur after the header. Some databases and bioinformatics applications do not recognize these comments and follow the NCBI FASTA specification. An example of a multiple sequence FASTA file follows:
=== Biotransformation === n-Hexane is biotransformed to 2-hexanol and further to 2,5-hexanediol in the body. The conversion is catalyzed by the enzyme cytochrome P450 utilizing oxygen from air. 2,5-Hexanediol may be further oxidized to 2,5-hexanedione, which is neurotoxic and produces a polyneuropathy. In view of this behavior, replacement of n-hexane as a solvent has been discussed. n-Heptane is a possible alternative.
=== Charles and Francis Darwin (1880) === Although known primarily for his work on the Theory of Evolution, Charles Darwin was also keenly interested in plants. Through the 1870s, he and his son Francis studied the movement of plants towards light. They were able to show that light is perceived at the tip of a young stem (the coleoptile), whereas the bending occurs lower down the stem. They proposed that a 'transmissible substance' communicated the direction of light from the tip down to the stem. The idea of a 'transmissible substance' was initially dismissed by other plant biologists, but their work later led to the discovery of the first plant hormone. In the 1920s Dutch scientist Frits Warmolt Went and Russian scientist Nikolai Cholodny (working independently of each other) conclusively showed that asymmetric accumulation of a growth hormone was responsible for this bending. In 1933 this hormone was finally isolated by Kögl, Haagen-Smit and Erxleben and given the name 'auxin'.
U.S. authorities reported a spike in killings, kidnappings, and home invasions connected to Mexican cartels, and at least 19 Americans were killed in 2008. Another 92 Americans were killed between June 2009 and June 2010. The U.S. Joint Forces Command noted in a December 2008 report that the conflict will have a major impact on the stability of the Mexican state over the next several years, and therefore would demand an American response based on the implications for homeland security alone. After the JFC broached this issue in its 2008 report, several journalists and academics have discussed the possibility that Mexico could become a failed state. The Mexican government responded negatively to the U.S. government raising the prospect of Mexico becoming a failed state. To smooth over relations with Mexico over this issue, Secretary of State Hillary Clinton personally visited Mexico City in March 2009, followed by a visit by President Barack Obama a month later.
Sources: en.wikipedia.org
=== Differential diagnosis === Juvenile idiopathic arthritis may closely resemble the clinical presentation of some osteochondrodysplasias or genetic skeletal dysplsias. In that, both conditions can present with swollen, stiff and deformed joints. Type II collagen disorders are caused by variants in the COL2A1 gene. Type II collagen disorders can result in mild disease or severe which can cause death within weeks of birth. Infants with the severe form of the disease would be born with clear indications of the disease, such as disproportionate short stature, skeletal dysplasia, distinctive eye abnormalities, cleft palate, and others. However, infants with mild disease may only experience arthritis at birth, but may progress to more severe disease later in life. Early diagnosis can be challenging. Furthermore, type II collagenopathies have significant phenotypic overlap with conditions such as MPS. Guidelines are available to ensure healthcare professional are aware of the conditions and the symptoms of disease to support efficient diagnosis.
There has been uncertainty about which biological target interactions mediate the psychoactive and other effects of ibogaine. Rodent drug discrimination studies with ibogaine have been employed to help elucidate these interactions. Ibogaine partially substitutes for the serotonergic psychedelics LSD and DOM and this can be blocked by the serotonin 5-HT2 receptor antagonist pizotifen. Similarly, LSD and DOM partially substitute for ibogaine and this can be blocked by the serotonin 5-HT2A receptor antagonist pirenperone. The serotonin releasing agent and potent serotonin 5-HT2 receptor agonist fenfluramine also partially substitutes for ibogaine. The preferential serotonin 5-HT2C receptor agonists MK-212 and mCPP partially substitute for ibogaine as well and this can be blocked by the serotonin 5-HT2 receptor antagonist metergoline. The preceding findings suggest that serotonin 5-HT2A and 5-HT2C receptor activation are involved in the subjective effects of ibogaine. Conversely, the serotonin 5-HT1A and 5-HT3 receptors do not appear to be involved. Although serotonin 5-HT2A receptor signaling appears to be involved in the effects of ibogaine, neither ibogaine nor its major active metabolite noribogaine appears to act as a direct serotonin 5-HT2A receptor agonist. In addition, in contrast to the findings in drug discrimination studies, ibogaine fails to produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.
Donkey milk has been used by humans for alimentary and cosmetic purposes since Egyptian antiquity. Doctors recommended it to treat several afflictions because of its supposed healing and cosmetic virtues. Hippocrates (460–370 BC) was the first to write of the medicinal use of donkey milk and prescribed it for numerous conditions, including poisoning, fevers, infectious diseases, edema, wounds, nose bleeds, and liver trouble. In the Roman era, donkey milk was a recognized remedy; Pliny the Elder (23–79 AD) in his encyclopedic work, Naturalis Historia, wrote extensively about its health benefits, i.e. to fight fever, fatigue, eye strain, weakened teeth, face wrinkles, poisonings, ulcerations, asthma, and certain gynecological troubles. However, it was not until the Renaissance that the first real scientific consideration was given to donkey milk. Georges-Louis Leclerc the Comte de Buffon (1707–1788) mentions the benefits of donkey milk in his Histoire naturelle and Pauline Bonaparte (1780–1825), Napoleon's sister, is reported to have used donkey milk for skin care. In France in the nineteenth century, Dr. Parrot of the Hospital des Enfants Assistés spread the practice of bringing motherless babies directly to the donkey's nipple (Bulletin de l’Académie de médicine, 1882). Donkey's milk was sold until the twentieth century to feed orphaned infants and to cure delicate children, the sick, and the elderly. For this reason, there were many donkey farms in Italy, Belgium, Germany, and Switzerland.
Sources: en.wikipedia.org
== Materials and technique == Many variables impact decisions about thread weight, stitching method, and stitch length. Some of these variables include "the size of the loss, desired aesthetic and type of stitching thread." The conservator must weigh the impact of the stitching on the textile. Another consideration is the spacing of the stitches. Higher density stitching is more robust but less elastic and creates more holes in the fabric. Low-density stitching is weaker, is more flexible, and produces fewer holes. Conservation stitching must balance the needs of the textile in question with the impact the process of stitching will have on the object. A best practice is to plan out the intended stitches and utilize any existing stitching holes in the textile. It is essential that all methods of stabilizing the textile be appropriately documented. Stitching methods: There are many methods of stitching used in textile conservation. A great resource with videos on each method can be found on the CCI video "Stitches Used in Textile Conservation." Whip stitch is employed to join two fabrics. If the stabilizing fabric is not wide enough to cover the entire loss area, the whip stitch can join two pieces of stabilizer or any two fabrics.selvages. Straight stitch attaches a stabilizing fabric to large textiles and evenly distributes the weight hold large textiles to a new backing fabric while distributing the weight of the textile evenly. The stitch is small, nearly invisible on the top of the textile with a longer stitch length on the back.
== Tissues distribution == Studies have reported that humans express FFAR3 in their: (a) enteroendocrine L cells and K cells of the intestines; (b) endothelium of blood vessels in the frontal cortex of the brain, pancreatic β-cells, and adipose. i.e., fat, tissue (but not in mouse adipose tissue); (c) the vascular endothelium of the myometrium, the epithelium of the amnion, chorion and placenta, and certain immune cells in these tissues of pregnant women; (d) the hippocampus of the brain; (e) sympathetic ganglia, i.e., autonomic ganglia of the sympathetic nervous system; (f) certain types of immune cells, i.e., blood monocytes (but not mouse monocytes), basophils, dendritic cells derived from human monocytes isolated from whole blood, and the tissues containing these blood cells, i.e., the bone marrow, spleen, lymph nodes, and thymus; and (g) alveolar macrophages, and macrophages in various other tissues; and (h) certain immortalised cell lines, i.e., MCF-7 breast cancer, HCT116 colorectal cancer, HEK293 embryonic kidney, U937 leukemic promonocyte, THP-1 leukemic monocyte, EoL-1 leukemic eosinophil, Jurcat leukemic T lymphocyte, MOLT-4 T lymphoblast leukemic, and HL60 acute myeloid leukemia cells (but only when the HL60 cells are pre-treated with phorbol 12-myristate 13-acetate to promote their cellular differentiation). As noted, the expression of FFAR3 in the cells and tissues of animals are not always the same as those in humans.
She remained in Australia for the next decade, discovering a number of new plant and animal species in the process, but also became notorious in later years for her removal of Aboriginal skeletons – and the possible incitement of violence against Aboriginal people – for anthropological research purposes. 1865: English geologist Elizabeth Carne was elected the first female Fellow of the Royal Geological Society of Cornwall. 1869: British physician and suffragist Sophia Jex-Blake led the successful campaign for women to be allowed to enrol in university medical training in the UK. Subsequently the University of Edinburgh became the first British university to admit women and Jex-Blake became the first practising female doctor in Scotland.
Elly Crampton Chuquimia Quiñones-Tancara, Aymara name Chuquimamani-Condori, is an American electronic music artist, poet and composer. Their music, which combines elements of Andean music and cumbia with electronic music and American genres like crunk and R&B, explores Andean cultural concepts and Latin American queer theory. They make up one half of Los Thuthanaka, along with their brother Joshua Chuquimia Crampton. The two siblings identify with the Pakajaqi nation of Aymara people. In 2025, they were awarded the Venice Biennale Silver Lion award following the release of Los Thuthanaka's self-titled album that spring. The album was named by Pitchfork as the best album of 2025.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.